Fundraise

Fresenius raises €523M from FMC share sale to fund growth

What's the deal? FreseniusDealroom has a profile for this one. Try Dealroom → placed about 13.4 million Fresenius Medical Care (FMC)Dealroom has a profile for this one. Try Dealroom → shares at €39 each, raising just under €523 million and trimming its stake from roughly 25% to 20%. The accelerated bookbuilding, aimed at institutional investors, was several times oversubscribed, according to Handelsblatt. The package equals about 5% of FMC's issued share capital.

Why now? The sale follows an earlier €300 million disposal of FMC stock in August 2026, extending the gradual unwinding of a stake Fresenius has held as a financial investment since deconsolidating the dialysis business in November 2023.

What's the endgame? Chief executive officer Michael Sen has framed the disposal as freeing up room for the group's growth platforms, with net proceeds to be deployed in line with Fresenius's capital allocation priorities. The pricing carried a 4.4% discount to FMC's previous Xetra close; a 90-day lock-up now caps further sales of the residual position.

What else? The move lands amid upgraded guidance. On November 4, Fresenius lifted its full-year outlook, now expecting group EBIT margin above 11.5% and currency-adjusted core earnings-per-share growth in the upper half of its 10–15% range. Third-quarter group EBIT reached €638 million, a currency-adjusted gain of 10%, led by its KabiDealroom has a profile for this one. Try Dealroom → and Helios units.

The pipeline: A November 2 collaboration with WuXi Biologics gives Fresenius exclusive access to up to 37 potential biosimilar candidates, which could expand its portfolio from 29 to as many as 66 molecules over the coming decade. Fresenius secures worldwide marketing rights for selected products; WuXi handles development on a fee basis.

The signal: Analysts responded quickly. Jefferies raised its target to €62 from €55, keeping a "Buy" rating, while two other houses lifted targets to €58 and €58.50, citing the quarterly report and WuXi deal. The shares still slipped 1.1% in trading, suggesting the real test lies less in the sale than in what the redeployed cash delivers.

Read more: ad-hoc-news.de

Image credit: Bhakua

More top stories